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Abstract. 
 
Vaults and telomerase are ribonucleoprotein
(RNP) particles that share a common protein subunit,
TEP1. Although its role in either complex has not yet
been deﬁned, TEP1 has been shown to interact with the
mouse telomerase RNA and with several of the human
 
vault RNAs in a yeast three-hybrid assay. An 
 
mTep1
 
2/2
 
mouse was previously generated which resulted in no
apparent change in telomere length or telomerase ac-
tivity in six generations of 
 
mTep1
 
-deﬁcient mice. Here
we show that the levels of the telomerase RNA and its
association with the telomerase RNP are also unaf-
 
fected in 
 
mTep1
 
2
 
/
 
2
 
 mice. Although vaults puriﬁed from
the livers of 
 
mTep1
 
2
 
/
 
2
 
 mice appear structurally intact
by both negative stain and cryoelectron microscopy,
three-dimensional reconstruction of the 
 
mTep1
 
2/2
 
 vault
revealed less density in the cap than previously ob-
served for the intact rat vault. Furthermore, the ab-
sence of TEP1 completely disrupted the stable associa-
tion of the vault RNA with the puriﬁed vault particle
and also resulted in a decrease in the levels and stability
of the vault RNA. Therefore, we have uncovered a
novel role for TEP1 in vivo as an integral vault protein
important for the stabilization and recruitment of the
vault RNA to the vault particle.
Key words: TEP1 • vaults • mouse embryonic stem
cells • RNA stability • cryo-EM 
 
Introduction
 
Mammalian vaults are large cytoplasmic RNP complexes,
composed of at least four components: the 104-kD major
vault protein (MVP),
 
1
 
 the 193-kD poly(ADP-ribosyl)
polymerase VPARP, the telomerase/vault-associated pro-
tein TEP1, and one or more small RNAs (vRNAs) (Ke-
dersha and Rome, 1986). Identification of VPARP as a
functional poly(ADP-ribose) polymerase (PARP) pro-
vided the first evidence of a vault-associated enzymatic ac-
tivity (Kickhoefer et al., 1999a). The recent discovery of
TEP1 as an associated protein in both vaults and telom-
erase provides an intriguing link between these two RNP
complexes that is not yet understood (Harrington et al.,
1997a; Kickhoefer et al., 1999b). Vaults are widely distrib-
uted throughout eukaryotes and have a distinct morphol-
ogy that is highly conserved (for reviews see Rome et al.,
1991; Kickhoefer et al., 1996). Although the function of
the vault particle has remained elusive, several studies sug-
gest that it may be involved in some form of intracellular
transport (Scheffer et al., 1995; Hamill and Suprenant,
1997; Abbondanza et al., 1998; Herrmann et al., 1999; Ki-
tazono et al., 1999).
Purified vaults display an eightfold barrel-like symmetry
where the barrel is formed of multiple copies of the MVP,
with caps on each end postulated to contain VPARP,
TEP1, and the vRNAs (Kedersha et al., 1991; Kong et al.,
2000). Cryoelectron microscopy (cryo-EM) image recon-
struction of the 13-MD vault particle purified from rat
liver shows the interior of the particle to be hollow, lend-
ing support to a role as a carrier (Kong et al., 1999). Re-
cently, a reconstruction of RNase-treated vaults localized
the vRNA to the caps of the vault particle by difference
mapping (Kong et al., 2000). vRNAs have been cloned
from humans, rats, mice, and bullfrogs and their length
varies from 86 to 141 bases. Humans and bullfrogs contain
multiple related vRNAs (Kickhoefer et al., 1993, 1998).
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Previously we have shown that several of the human
vRNAs, in addition to the telomerase RNA, specifically
interact with TEP1 in the yeast RNA–protein interaction
assay (Harrington et al., 1997a; Kickhoefer et al., 1999b).
Although purified vaults contain TEP1, they do not pos-
sess telomerase activity (Kickhoefer et al., 1999b).
Most eukaryotic chromosome ends are maintained by
telomerase, a multisubunit RNP complex that uses an
RNA template to specify the addition of telomeric DNA
onto the chromosome ends (for review see Greider, 1996).
The essential role of the telomerase RNA component in
providing a template for telomere DNA synthesis is well
established in eukaryotes. Biochemical studies indicate
that the human telomerase complex is 
 
.
 
1 MD, suggesting
that it contains numerous subunits in addition to the tel-
omerase catalytic component, telomerase reverse tran-
scriptase (TERT), and the human telomerase RNA (hTR)
(Nakayama et al., 1997; Schnapp et al., 1998). TEP1 was
initially identified as the mammalian homologue of the
 
Tetrahymena
 
 telomerase p80 protein (Harrington et al.,
1997a; Nakayama et al., 1997). Immunoprecipitates of
TEP1 possess telomerase activity and TEP1 is associated
with TERT and hTR (Harrington et al., 1997a,b; Na-
kayama et al., 1997). In vitro, the minimal complex neces-
sary for reconstitution of telomerase activity appears to
comprise TERT and hTR and does not require the addi-
tion of TEP1 (Weinrich et al., 1997; Beattie et al., 1998;
Holt et al., 1999).
Homologous recombination has been used to disrupt the
gene encoding 
 
mTep1
 
 (Liu et al., 2000). Despite the fact
that TEP1 is associated with the telomerase RNA and the
telomerase catalytic subunit TERT in vivo, 
 
mTep1-
 
defi-
cient mice showed no significant alteration in telomerase
activity or telomere length (Liu et al., 2000). Here we show
that biochemical fractionation of the telomerase complexes
and the level of telomerase RNA in cell extracts showed
no detectable alterations in 
 
mTep1
 
-deficient mice. Since
TEP1 is not unique to the telomerase complex, we ana-
lyzed the effect on the integrity of the vault particle and its
associated RNA, vRNA. Gross vault morphology appears
to be unaltered in 
 
mTep1
 
-deficient mice, as observed by
both negative stain and cryo-EM. A three-dimensional re-
construction of 
 
mTep1
 
-deficient vaults revealed less den-
sity in the cap and supports the localization of at least a
portion of TEP1 to the ends of the vault caps, placing it
next to the assigned location of vRNA. The absence of
TEP1 disrupted vRNA association with vaults and led to a
decrease in steady state levels of vRNA in all tissues exam-
ined. This decreased stability was reflected in a decrease in
the half-life of the vRNA. These data suggest that TEP1 is
important for vRNA binding and recruitment to the vault
complex, and that the vRNA association with TEP1 and/or
the vault complex appears to stabilize the vRNA.
 
Materials and Methods
 
mTep1-deficient Mice, Embryonic Stem Cells, and 
Mouse Embryonic Fibroblasts
 
The generation of 
 
mTep1
 
2/2
 
 homozygous animals has been described
elsewhere (Liu et al., 2000). A founder breeding pair of generation four
 
mTep1
 
2/2 
 
mice of mixed genetic background (129SvJ/C57BL) were used
to establish a colony at the University of California at Los Angeles. The
 
generation five mice were interbred to produce generation six offspring.
All mice used in this study were from generation six 
 
mTep1
 
2/2
 
 animals.
embryonic stem (ES) cell clones were generated from G418-resistant
 
mTep1
 
1/2
 
 ES cell clones by culturing with an increased G418 concentra-
tion (4 mg/ml) (Liu et al., 2000). Mouse embryonic fibroblast (MEF) cell
lines were obtained using the 3T3 protocol (Todaro and Green, 1963).
MEF 5 and 8 are two independent lines derived from 
 
mTep1
 
2/2
 
 mouse
embryos and MEF 11 cells were derived from a wild-type mouse embryo.
All three MEF lines were derived from the same litter.
 
Cell Lysate Preparation, Partial Purification of Mouse 
Telomerase, Telomerase Assays, and Quantitive Reverse 
Transcription PCR Analysis of Mouse Telomerase RNA
 
S-100 extracts from cultured ES cells were prepared as described (Prowse
et al., 1993). Approximately 37 mg of protein from each sample was ap-
plied to Sephacryl S-400 (Amersham Pharmacia Biotech) equilibrated in
2.3
 
3
 
 hypobuffer (23 mM Hepes, pH 8.0, 7 mM KCl, 2.3 mM MgCl
 
2
 
 includ-
ing 1 mM DTT, RNase, and protease inhibitors). Individual fractions from
each sample were measured for telomerase activity and the presence of
mouse telomerase RNA (mTR). Telomerase activity was assayed using the
telomere repeat amplification procotol (TRAP) (Kim et al., 1994) follow-
ing the manufacturer’s instructions (Intergen, Inc.). TRAP was performed
on the individual fractions from each sample for 20 PCR cycles. The
amount of mTR in each fraction was determined by a real time quantitative
reverse transcription (RT)-PCR analysis (Taqman) using ABI Prism 7700
Sequence Detection System (PE Biosystems). The sequences of the PCR
primers are 5
 
9
 
-GCCGCAAGGACAGGAATG, 3
 
9
 
-GGGTGCACTTC-
CCACAGC, and TGGTCCCCGTGTTCGGTGTCTTACC (probe). 
 
Vault Purification and Analysis
 
Vaults were purified from mouse liver as described previously (Kong et al.,
1999). However, the procedure was significantly scaled down due to the
limited quantities and size of mouse livers. Approximately 5–6 g of mouse
liver was used and all gradient steps were carried out using the AH650 ro-
tor (Sorvall) at 25,000 rpm. In the final purification step, vaults were puri-
fied over a single cesium chloride gradient to minimize sample loss, and the
purified vaults were pelleted at 100,000 
 
g
 
 using the Ti80 rotor (Beckman
Coulter) and resuspended in 
 
z
 
125 
 
m
 
l of 0.09 M MES, pH 6.5 containing
PMSF. Purified vaults (20 
 
m
 
l) were analyzed by SDS-PAGE followed by
silver staining or immunoblot analysis. All antibodies (anti-MVP, anti-
VPARP, and anti-TEP1) have been described previously and were used
accordingly (Kickhoefer et al., 1999a,b). EM of uranyl acetate stained
vaults was carried out as described previously (Kedersha and Rome, 1986).
 
RNA Isolation and Northern Analysis
 
Total RNA was isolated from various tissues or MEF cell lines using RNA
STAT (Tel-test, Inc.) following the manufacturer’s protocol. Total RNA
(25 
 
m
 
g) was fractionated on 6% acrylamide–8 M urea gel, electroblotted
to Zeta-Probe GT membrane (Bio-Rad Laboratories), and hybridized
with the indicated probes according to the manufacturer’s instructions.
Probes were prepared by random priming with the Prime-It II kit (Strat-
agene). The mTR probe is based on the wild-type mTR sequence (Blasco
et al., 1995). The mouse vault RNA (mVR) probe is based on the mouse
(Balb/c) vault RNA gene sequence (data available from GenBank/
EMBL/DDBJ under accession no. AY007237). Hybridizations were car-
ried out sequentially; membranes were stripped and hybridized to an end-
labeled oligonucleotide complimentary to the mouse 5S RNA gene
(AACCATGCCCGACCCTGCTTAGCTTC) to use as a loading control.
For actinomycin D (Sigma-Aldrich) experiments, the MEF cells were in-
cubated in fresh medium containing a 10-
 
m
 
g/ml concentration of the drug.
At the indicated times total RNA was isolated.
 
Cryo-EM and Image Processing
 
A 20-
 
m
 
l sample of vaults purified from 
 
mTep1
 
2/2
 
 mouse livers was used
for cryo-EM. Holey carbon grids were glow discharged and then 4 
 
m
 
l of
the vault sample was applied to each grid, blotted with filter paper, and
then plunged into ethane slush chilled by liquid nitrogen (Adrian et al.,
1984). Digital micrographs were collected on a Philips CM120 transmission
electron microscope equipped with an LaB6 filament, Gatan cryo-accesso-
ries, and a Gatan slow-scan CCD camera (1,024 
 
3
 
 1,024 pixels, YAG scin-
tillator). The nominal microscope magnification was 45,000, yielding a digi-
tal pixel size of 4.1 Å on the molecular scale. All images were collected 
Kickhoefer et al. 
 
Vault RNA Stability Requires TEP1
 
159
 
with a defocus value of 
 
2
 
1.0 
 
m
 
m giving a first CTF zero of 19 Å. CTF cor-
rection was carried out as described previously (Kong et al., 2000).
Image processing was performed on DEC/Compaq alpha workstations
and a Silicon Graphics Reality Monster supercomputer with 32 proces-
sors. The QVIEW software package (Shah and Stewart, 1998) was used to
extract individual vault particle images into 200 
 
3
 
 200 pixel fields. A pre-
liminary set of 305 particle images was used to calculate Euler angles using
the angular reconstitution method in the IMAGIC software package (van
Heel et al., 1996). Initially cyclic eightfold symmetry was assumed and a
preliminary reconstruction was calculated with imposed cyclic eightfold
symmetry. This reconstruction showed strong features of dihedral eight-
fold symmetry, implying that the upper and lower halves of the vault are
related by a twofold symmetry axis. Thus dihedral eightfold symmetry was
imposed during the subsequent refinement cycles. The third and final re-
finement cycle was performed with a 4
 
8
 
 anchor set spacing and a 1
 
8
 
 refine-
ment step size. The resolution of the final reconstruction, which was based
on 397 particle images, was 27 Å as assessed by the Fourier shell correla-
tion 0.5 threshold criterion (Böttcher et al., 1997; Conway et al., 1997).
A linear ramped elliptical mask was used during refinement of the
vault to remove internal contents as well as external noise surrounding the
particle. The inner ellipse had dimensions of 151 and 306 Å; the outer el-
lipse radii were 224 and 413 Å. The isosurface and the density slab repre-
sentations were generated using the AVS software package (Advanced
Visual Systems, Inc.). To select an appropriate isosurface level, the molec-
ular mass of the 
 
mTep1
 
2/2
 
 vault was assumed to be 11.8 MD. This mass
 
value was estimated from the average STEM mass measurement of 12.9
MD for the intact vault (Kedersha et al., 1991), minus 5% for the vRNA
(0.64 MD) and the mass of two copies of TEP1 (0.48 MD).
 
Results
 
mTep1 Is Not Essential for mTR Processing, Stability, 
or Association with Telomerase Complexes
 
Analysis of telomerase complexes from 
 
mTep1
 
2/2
 
 and
wild-type ES cells indicated that the absence of TEP1 did
not grossly affect the fractionation properties of telom-
erase complexes when examined by S-400 chromatogra-
phy (Fig. 1 A). Fractions were analyzed for telomerase ac-
tivity using the TRAP (Kim et al., 1994). Both wild-type
and 
 
mTep1
 
-deficient telomerase activities paralleled each
other with activities spread from fraction 28–50. No de-
tectable change in mTR fractionation with telomerase
complexes was observed using quantitative RT-PCR (Fig.
1 B). The slightly higher telomerase activity and higher
copy number of telomerase RNA from the 
 
mTep1
 
-defi-
Figure 1. mTR expression in mTep2/2 mice. (A) Telomerase activ-
ity in the individual Sephacryl S-400 fractions of wild-type (1/1)
and mTep1-deficient (2/2) ES cell lysates. TRAP was performed
for 20 PCR cycles on 5 ml of each fraction of the indicated genotype.
An internal PCR standard for the TRAP is shown at bottom right
with an arrow. R represents the RNase A treatment of 5 ml of the fraction with
the peak telomerase activity. Peak fractions of the sizing standards thyroglobu-
lin, catalase, and aldolase are indicated above. (B) RT-PCR quantitation of
mTR in the individual fractions of wild-type (1/1) and mTep1-deficient
(2/2) ES cell lysates. The Taqman assay was performed on 5 ml of each frac-
tion of the indicated genotype. The relative copies of mTR were calculated
based on a standard curve using serial diluted mouse, total RNA, and/or the
fraction with the peak telomerase activity. The fraction with the peak telom-
erase activity had no detectable mTR after the RNase A treatment (data not
shown). (C) Northern blot analysis of total RNA prepared from brain, kidney,
and liver tissue at the indicated postnatal developmental stages (day 0 is new-
born). As a control, total RNA from adult wild-type testes was prepared. The
membrane was probed with mTR (top), stripped, and reprobed with an anti-
sense 5S oligonucleotide as a loading control (bottom). 
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cient ES fractions in Fig. 1, A and B, were not reproduc-
ible. In other experiments, we did not observe a difference
in the level of telomerase RNA or activity between the
wild-type and 
 
mTep1
 
-deficient ES cells (Liu, Y., and L.
Harrington, data not shown). Since both telomerase com-
plex fractionation and mTR levels are unaffected in
 
mTep1
 
-deficient ES cells, we next determined whether
the developmental profile of mTR expression varied in
 
mTep1
 
2/2
 
 mice. Total RNA was isolated from brain, kid-
ney, and liver from 
 
mTep1
 
2/2
 
 mice at different postnatal
development stages up to 16 d after birth (Fig. 1 C). mTR
RNA was expressed in all tissues examined at birth and
decreased rapidly after birth in 
 
mTep1
 
2/2
 
 
 
mice, while 5S
RNA levels remained unchanged. These results are similar
to the previously published developmental RNA profile of
mTR in wild-type mice where mTR levels also rapidly de-
clined postnatally (Blasco et al., 1995).
 
Vaults Isolated from TEP1
 
2/2
 
 Mice Appear 
Structurally Intact
 
To ascertain the role of TEP1 in vault particle formation
in vivo, we purified vaults from the livers of wild-type and
 
mTep1
 
2/2
 
 mice (see Materials and Methods). Vault levels,
composition, and structure (assayed by negative stain EM)
remained constant in all wild-type mouse strains tested
(C57BL, 129SvJ, and Balb/c; data not shown). Vault com-
ponents from 
 
mTep1
 
2/2
 
 mice purified with identical prop-
erties as wild-type vaults through a series of gradient and
centrifugation steps (data not shown). Gel electrophoresis
and silver staining of highly purified vault fractions from
 
mTep1
 
2/2
 
 
 
and wild-type mouse livers showed comparable
amounts of MVP and VPARP (Fig. 2 A, Silver), whereas
the 
 
mTep1
 
2/2
 
 vault preparation, as expected, lacked TEP1
(Fig. 2 A, Silver). The absence of TEP1 in the vault prepa-
ration from 
 
mTep1
 
2/2
 
 mice was also confirmed by immu-
Figure 2. Purified vaults. (A) Silver stain of vaults purified from
livers of either wild-type (1/1) or mTep1-deficient (2/2) mice
(arrows indicate TEP1, VPARP, and MVP). The identities of the
vault proteins were confirmed by immunoblot analysis using the
indicated antibodies (a-TEP1, a-VPARP, and a-MVP). Due to
limited sample availability immunoblots were stripped and re-
probed with the different antibodies. Consequently, the MVP an-
tibody was not completely removed and MVP reappeared in sub-
sequent reprobing with TEP antibodies. As expected, TEP1 is
absent in the mTep1-deficient mice. The anti-VPARP antibody
was made against a portion of the human VPARP protein and
recognizes the mouse VPARP protein here as a smear. (B) Elec-
tron micrographs of negatively stained vaults purified from either
wild-type (1/1) or mTep1-deficient (2/2) mice. Bar, 100 nm.
Figure 3. Cryo-EM recon-
struction of vaults purified
from  mTEP1-deficient mice.
(A) A portion (640 3 640
pixels) of a digital cryoelec-
tron micrograph of the
vaults. (B) A surface repre-
sentation of the final recon-
struction at 27 Å resolution.
The two black lines indicate
the position of the density
slab shown in C. (C) A two-
dimensional projection of a
density slab through the top
of the cap of the mTep12/2
vault reconstruction. KO,
knockout. (D) The corre-
sponding density slab from
the RNase-treated rat vault
reconstruction (Kong et al.,
2000). The dashed white cir-
cles in C and D outline the
intermediate ring region in
which a major difference is
observed between the two
reconstructions. Bars: (A)
1,000 Å; (B) 250 Å. 
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noblotting of the purified vaults with antibodies against
each individual vault protein component (anti-MVP, anti-
VPARP, and anti-TEP1 antibodies, Fig. 2 A). Due to lim-
ited sample availability immunoblots were stripped and
reprobed with the different antibodies. Consequently, the
MVP antibody was not completely removed and MVP re-
appeared in subsequent reprobing with the anti-TEP1 an-
tibody. As expected, TEP1 is absent in the 
 
mTep1
 
-defi-
cient mice (Liu et al., 2000). EM of negatively stained
purified preparations from mouse liver showed that vault
structures from the 
 
mTep1
 
2/2
 
 mice were indistinguishable
from those purified from wild-type mice (Fig. 2 B).
 
Cryo-EM Reconstruction of mTep1
 
2/2
 
 Vault Reveals 
Reduced Cap Density
 
Purified 
 
mTep1
 
2/2
 
 vaults were flash frozen on holey car-
bon EM grids and cryoelectron micrographs were col-
lected (Fig. 3 A). Images of 397 vault particles were com-
putationally combined to generate a three-dimensional
reconstruction of the 
 
mTep1
 
2/2
 
 vault at 27-Å resolution.
A surface representation of the reconstruction (Fig. 3 B)
shows that the overall structure of the 
 
mTep1
 
2/2 
 
vault is
similar to that of both the intact and RNase-treated rat
vaults (Kong et al., 1999, 2000). Careful examination of
the density slices revealed that the strong cap density at-
tributed to the vRNA is lacking in the reconstruction of
the 
 
mTep1
 
2/2
 
 vault. When the 
 
mTep1
 
2/2
 
 vault and the
RNase-treated rat vault reconstructions are compared, mi-
nor differences are found throughout the structures that
are probably attributable to subtle variations between spe-
cies. However, a major difference between the two recon-
structions is observed in a density slab through the top of
the cap (Fig. 3 B). Within this slab, both reconstructions
show the same pattern of 16 strong density spots around
the outermost edge. However, less density is observed in
the mouse 
 
Tep1
 
2/2
 
 vaults within an intermediate ring (Fig.
3, C and D). This difference likely corresponds to the posi-
tion of the TEP1 protein at the end of the vault cap, a loca-
tion for TEP1 previously predicted from structural model-
ing (Kong et al., 2000).
 
mTep1 Is Essential for Stable Interaction of Vault 
RNAs with the Vault Particle
 
We next examined the purified vault fractions for the pres-
ence of associated vRNA. Previously it has been shown
that the vRNA is not required for the structural integrity
of the vault particle (Kedersha et al., 1991; Kong et al.,
2000). Northern blot analysis revealed the complete ab-
sence of vRNA in vaults purified from 
 
mTep1
 
2/2
 
 mice
compared with wild-type vaults (Fig. 4, compare lanes 3
and 6). Since vault purification takes several days to com-
plete, we were concerned about the possibility that the
vRNA was degraded during the isolation procedure. To
test this possibility we examined early fractions during
vault purification for the presence of the vRNA. Vaults
are known to pellet at 100,000 
 
g
 
 (P100) and previous stud-
ies have shown that the vRNA is present in both the P100
and the supernatant (S100) fractions (Kickhoefer et al.,
1998). Northern analysis indicated that as expected the
vRNA is present in both S100 and P100 fractions with
about twice as much RNA associated with the S100 frac-
tion compared with the P100 in the wild-type mice (Fig. 4,
lanes 4 and 5). In contrast, only a trace amount of vRNA is
present in the P100 extract from the livers of 
 
mTep1
 
2/2
mice (Fig. 4, lane 2). However, the amount of vRNA in the
S100 extract from the mTep1-deficient mice is comparable
to that seen in wild-type mice S100 extract (Fig. 4, lanes 1
and 4). These data support the hypothesis that TEP1 is re-
sponsible for the vRNAs stable association with the vault
particle and suggest that vRNA levels may be altered in
mTep1-deficient mice.
A comparison of vRNA levels in mTep12/2 and wild-
type mouse tissues revealed vRNA levels to be three- to
fivefold lower in mTep1-deficient mice (Fig. 5 A). One ex-
planation for this variable expression level could be due to
a difference in vRNA levels between wild-type mice
(C57BL/6) and the mixed genetic background of the
mTep1-deficient mice (Liu et al., 2000). Several mouse
strains were analyzed to determine whether vRNA levels
varied, and no difference was found (Fig. 5 B). The blots
were stripped and hybridized for 5S RNA as a loading
control (Fig. 5, A and B). 5S RNA levels also do not vary
Figure 4. Vault RNA associ-
ation with vaults. Northern
analysis of RNA purified
from subcellular fractions
during vault purification
from wild-type (1/1) and
mTep1-deficient (2/2)
mice. S100 (100,000 g super-
natant, lanes 1 and 4), P100
(100,000 g pellet, lanes 2 and
5), and purified vaults (Vts,
lanes 3 and 6).
Figure 5. Comparative vault RNA ex-
pression in mTep1-deficient and wild-
type mouse tissues. (A) Northern anal-
ysis of RNA prepared from the indicated
tissues of wild-type (1/1) and mTep1-
deficient (2/2) mice. The membrane
was probed with mVR (top), stripped,
and reprobed with an antisense 5S oli-
gonucletide (bottom) to control for
loading. (B) Northern analysis of RNA
prepared from different mice strains as indicated, and probed as
indicated above. mVR expression does not vary significantly in
the different wild-type strain backgrounds.The Journal of Cell Biology, Volume 152, 2001 162
between the mTep12/2 and wild-type mice. These data
suggested that the lower steady state level of vRNA might
be due to a change in the stability of the vRNA in the
mTep12/2 mice.
To analyze the stability of the vRNA we used several
MEF cell lines obtained using the 3T3 protocol (Todaro
and Green, 1963). MEF 5 and 8 are two independent lines
derived from mTep12/2 mouse embryos, MEF 11 cells are
derived from a wild-type mouse embryo, and all three
MEF lines are derived from the same litter. MEF cells were
treated with actinomycin D to inhibit transcription and to-
tal RNA was isolated at different time intervals after drug
treatment (30 min, 1, 2, 4, 6, and 8 h). Northern analysis re-
vealed that the vRNAs stability is reduced in the mTep12/2
MEF lines compared with the wild-type MEF lines. In
wild-type MEF cells, vRNA has a half-life of 4–6 h; how-
ever, in both mTep12/2 MEF lines, the vRNAs half-life is
reduced to 0.5–1 h (Fig. 6, mVR). The blots were stripped
and reprobed with either mTR or 5S (a loading control).
No effect is seen on the stability of the mTR (Fig. 6). How-
ever, previous analysis has suggested that the telomerase
RNA possesses a half-life of 24 h or longer; therefore, un-
der these experimental conditions a subtle effect on mTR
half-life may not be detected (Yi et al., 1999).
Discussion
We have found that in the absence of TEP1 the vRNA is
no longer stably associated with vaults. In addition, the ap-
parent half-life of the vRNA is reduced by severalfold. In
contrast, the association of mTR with telomerase activity
and the developmental expression profile of mTR was un-
altered. TEP1 has been shown to interact with mTR and
several human vRNAs using the yeast RNA–protein inter-
action assay and its association with hTR in vivo has been
demonstrated (Harrington et al., 1997a,b; Nakayama et
al., 1997; Kickhoefer et al., 1999b). Apparently, the ab-
sence of TEP1 has no obvious effect on telomerase activ-
ity, telomere length, or the levels of mTR in vivo (Liu et
al., 2000). If TEP1 were associated with only a fraction of
the mTR in the cell, its disruption might have no pheno-
typic consequences in vivo. Alternatively, other telom-
erase RNA binding proteins may share a redundant role
with TEP1 in telomerase complex assembly. In support of
this hypothesis is the recent identification of two addi-
tional telomerase RNA binding proteins, hStau and L22.
Each of these proteins immunoprecipitates telomerase ac-
tivity and hTR, but not each other or TEP1, suggesting
that there may be multiple functional telomerase com-
plexes (Le et al., 2000).
Although the role of TEP1 in the telomerase complex ap-
pears to be redundant, its function in the vault complex is
not. At least six independent vault preparations have been
carried out on mTep1-deficient mice and the vault proteins
purified with properties identical to those of wild-type
vaults through several centrifugation and gradient fraction-
ations. The vaults from the mTep1-deficient mice have the
typical lobular morphology as observed by negative stain
EM, suggesting that TEP1 is not essential for vault particle
formation. Previously we proposed that the 16 WD40 re-
peats of TEP1 might play a role in organizing the eightfold
symmetry of the vault (Kong et al., 2000), although this
does not appear to be the case in light of our data.
To examine the structure of the vault from mTep1-defi-
cient mice more closely, we performed cryo-EM and
three-dimensional image reconstruction. We noted that
the  mTep12/2 vault was most similar to the RNase-treated
rat vault, in which the vRNA was reduced to below detect-
able levels (Kong et al., 2000). This finding is consistent
with our observation that vRNA does not stably associate
with the mTep12/2 vault. The most significant difference
between the mTep12/2 vault and the RNase-treated vault
was found at the ends of the vault caps. This difference
corresponds to the region in the RNase-treated vault re-
construction where we previously observed 16-fold density
and modeled the 16 WD40 repeat domain of TEP1 (Kong
et al., 2000). The reconstruction of the Tep1-deficient vault
supports the localization of at least a portion of TEP1 to
the ends of the vault caps, placing it next to the assigned
location of vRNA.
We have observed an abrogation of the vRNA in puri-
fied vaults from Tep1-deficient mice. Our findings indicate
that TEP1 is a critical protein involved in vRNA binding
and that TEP1 is largely responsible for localizing and sta-
bilizing vRNA association with vault particles. The role of
the vRNA in vault particle function is not yet understood.
However, the vRNA is not a structural component, as its
degradation does not alter vault structure (Kedersha et al.,
1991; Kong et al., 2000). It remains possible that in the
Tep1-deficient mice the vRNA may partly contribute to
vault function, since a small portion of vRNA is present in
the 100,000 g pellet (P100) and could be unstably associ-
ated with the vault particle. In vaults, TEP1 appears to fa-
cilitate the vault RNA’s localization to the particle.
It is not clear whether the stabilizing effect of TEP1 on
vRNA is through direct binding or through localizing
vRNA to the vault particle where it is subsequently pro-
tected from degradation. It is possible that TEP1 functions
in the localization of other RNAs to RNP complexes. Re-
duced levels of other small RNAs have been observed for
several disrupted RNP complexes. The Sm proteins are re-
quired for wild-type levels of U snRNAs (Rymond, 1993;
Xue et al., 2000) and the Sm-like proteins are required for
U6 snRNA accumulation (Pannone et al., 1998; Mayes et
Figure 6. Vault RNA expression varies in actino-
mycin D–treated MEFs. Northern analysis of RNA
prepared from wild-type (MEF111/1) and mTep1-
deficient (MEF82/2 and MEF52/2) cells treated
with actinomycin D for the indicated times. The
membrane was probed with mTR (top), stripped,
and reprobed first with mVR (middle) and next
with an antisense 5S oligonucleotide (bottom). Con-
trol (C) samples were not treated with drug.Kickhoefer et al. Vault RNA Stability Requires TEP1 163
al., 1999; Salgado-Garrido et al., 1999). Disruption of the
gene encoding Ro in Caenorhabditis elegans led to re-
duced levels of Y RNAs in mutant worms (Labbé et al.,
1999). Disruption of several of the signal recognition parti-
cle proteins in the yeast Saccharomyces cerevisiae leads to
decreased levels of ScR1 RNA, reduced signal recognition
particle protein levels, and inefficient protein transloca-
tion across the ER membrane (Brown et al., 1994).
Are the differences in telomerase RNAs and vRNAs the
reason TEP1 affects them differently? Each RNA is tran-
scribed by a different class of RNA polymerase. vRNA is
transcribed by RNA polymerase III and contains the clas-
sical features of a polymerase III gene, including an inter-
nal A and B box with a stretch of T’s at the 39 end typical
for transcription termination (Kickhoefer et al., 1993). In
contrast, RNA polymerase II presumably transcribes the
hTR and mTR genes (Hinkley et al., 1998; Zhao et al.,
1998). Recently, 32 vertebrate telomerase RNAs were ana-
lyzed and a phylogenic comparative analysis predicted a
secondary structure that contains four conserved structural
domains with 10 helical regions of the RNA being univer-
sally conserved (Chen et al., 2000). One of the conserved
structural domains contains a sno-RNA Box H/ACA ele-
ment that is thought to be necessary for telomerase RNA
stability, processing, and possibly for assembly into func-
tional telomerase complexes (Mitchell et al., 1999a). In-
deed, a portion of telomerase RNA has been localized to
the nucleolus and mutation of the Box H/ACA element re-
sults in decreased stability of telomerase RNA (Mitchell et
al., 1999a; Narayanan et al., 1999). Dyskerin, a component
of H/ACA snoRNPs, was recently shown to interact with
hTR (Mitchell et al., 1999b). Mutation in the human dys-
kerin gene leads to decreased steady state levels of hTR,
reduced telomerase activity, and shortened telomeres in
cells taken from two patients with the disorder dyskerato-
sis congenita (Mitchell et al., 1999b). However, the level of
three other H/ACA snoRNAs was unaffected in the dys-
keratosis congenita cells. These data suggest that dyskerin
has a role in telomerase RNA biogenesis and possibly in
telomerase RNP assembly. The secondary structure of
vRNAs has not yet been solved, but all known sequences
can be folded into similar structures that contain several
stem loops (Kickhoefer et al., 1993; Kickhoefer, V.A., and
L.H. Rome, unpublished observations).
There is no obvious sequence conservation between
vRNAs and hTR; therefore, it is not yet clear what deter-
mines the recognition of telomerase RNA or vRNA by
TEP1. It is not yet known whether vRNAs and telomerase
RNAs bind to separate sites on TEP1 or compete for bind-
ing to the same site. Despite the redundancy of TEP1 in
the telomerase complex but not the vault particle, our
studies reveal the first phenotype associated with the dis-
ruption of TEP1 and provide an important first step in elu-
cidating the physiological role of TEP1 in RNA assembly,
localization, and RNP function.
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